# Roivant (ROIV) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ROIV
## Company Profile
- Ticker: ROIV
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 34.93 USD
- Market cap: 20319388376.25 USD
- Last updated: 2026-09-04
## Business Overview
### Vant Operating Model
Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities.
### Brepocitinib Autoimmune Franchise
Brepocitinib is an oral JAK1/TYK2 inhibitor under FDA review for dermatomyositis. Priovant is also developing it in late-stage studies for non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris.
### IMVT-1402
Immunovant's IMVT-1402 is a fully human anti-FcRn antibody for IgG-mediated autoimmune diseases. Its clinical portfolio spans Graves' disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sjogren's disease and cutaneous lupus erythematosus.
### Mosliciguat
Pulmovant is developing mosliciguat, an inhaled soluble guanylate-cyclase activator, for pulmonary hypertension associated with interstitial lung disease.
### RNA-Delivery Intellectual Property
Genevant contributes lipid-nanoparticle technology and an associated intellectual-property portfolio for RNA delivery, adding a technology-licensing and patent-enforcement component to Roivant's operating model.
## Why The Stock Is Moving

The latest monitored company update is “Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the E….” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Commercial launch of brepocitinib in dermatomyositis by the end of September 2026, subject to FDA approval.
- Topline Phase 3 data for brepocitinib in non-infectious uveitis in the second half of 2026.
- Topline proof-of-concept data for IMVT-1402 in cutaneous lupus erythematosus in the second half of 2026.
- Topline Phase 2 data for mosliciguat in PH-ILD in the second half of 2026.
- Topline data from potentially registrational IMVT-1402 studies in Graves' disease and myasthenia gravis in 2027.
- Topline data from the brepocitinib Phase 3 cutaneous-sarcoidosis study and IMVT-1402 studies in CIDP and Sjogren's disease in 2028.

## Drug Assets

- IMVT-1402

## Recent News
- 2026-09-06 05:00 EST — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553) — Source: Roivant
- 2026-08-27 19:29 EST — [Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.](https://biopharmsignal.com/news/ROIV/roivant-announces-fda-approval-of-lisraya-brepocitinib-for-adults-with-dermatomy-c41f2ccf) — Source: Roivant
- 2026-08-27 19:29 EST — [Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.](https://biopharmsignal.com/news/ROIV/priovant-announces-fda-approval-of-lisraya-brepocitinib-for-adults-with-dermatom-aeb72f3d) — Source: Roivant
- 2026-08-26 15:12 EST — [JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis](https://biopharmsignal.com/news/ROIV/jama-dermatology-publishes-skin-specific-outcomes-from-phase-3-valor-trial-of-br-9823c862) — Source: Roivant
- 2026-08-06 11:00 EST — [Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update](https://biopharmsignal.com/news/ROIV/roivant-reports-financial-results-for-the-first-quarter-ended-june-30-2026-and-p-456d14ce) — Source: Roivant